Xiao Shudan, Li Yinghui, Li Bo, Wang Haoxuan, Wang Kun, Yang SuMin
Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Institute of Chronic Diseases, College of Medicine, Qingdao University, Qingdao, People's Republic of China.
J Inflamm Res. 2025 Jul 12;18:9129-9143. doi: 10.2147/JIR.S526611. eCollection 2025.
Anthracyclines, renowned for their efficacy and widespread application as antitumor agents, have substantially contributed to the enhancement of cancer patients' survival rates. Nonetheless, anthracyclines predominantly account for the cardiotoxic effects, both acute and chronic, experienced by individuals undergoing cancer treatment. Anthracycline-induced cardiotoxicity (AIC) usually leads to progressive systolic dysfunction of the left ventricle, which may subsequently develop into heart failure and even death. Therefore, more stable, specific and sensitive auxiliary diagnostic biomarkers are needed. Non-coding RNAs, comprising long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are pivotal in regulating cardiac metabolism, apoptosis, and oxidative stress, emerging as key targets for cardiovascular disease prevention and treatment. This review encapsulates the recent advancements in the field of non-coding RNA research in AIC, highlighting the prospect of non-coding RNAs as potential biomarkers and therapeutic targets for the condition. These molecules are known to regulate key cardiac processes including metabolism, apoptosis, and oxidative stress, which are central to the pathology of AIC. The potential of these molecules as diagnostic and prognostic indicators is significant, with miRNAs, for instance, being studied for their role in resistance to chemotherapeutic drugs and their application in therapeutic strategies. The review underscores the importance of understanding the intricate mechanisms by which non-coding RNAs influence gene expression and contribute to the development and progression of AIC, offering new avenues for targeted therapies and personalized treatment plans.
蒽环类药物以其作为抗肿瘤药物的有效性和广泛应用而闻名,在提高癌症患者生存率方面做出了重大贡献。尽管如此,蒽环类药物主要导致癌症治疗患者出现急性和慢性心脏毒性作用。蒽环类药物诱导的心脏毒性(AIC)通常会导致左心室进行性收缩功能障碍,随后可能发展为心力衰竭甚至死亡。因此,需要更稳定、特异和敏感的辅助诊断生物标志物。非编码RNA包括长链非编码RNA(lncRNA)、微小RNA(miRNA)和环状RNA(circRNA),在调节心脏代谢、细胞凋亡和氧化应激中起关键作用,成为心血管疾病预防和治疗的关键靶点。本综述总结了AIC中非编码RNA研究领域的最新进展,强调了非编码RNA作为该疾病潜在生物标志物和治疗靶点的前景。已知这些分子可调节包括代谢、细胞凋亡和氧化应激在内的关键心脏过程,而这些过程是AIC病理的核心。这些分子作为诊断和预后指标的潜力巨大,例如,miRNA正在被研究其在化疗药物耐药性中的作用及其在治疗策略中的应用。该综述强调了理解非编码RNA影响基因表达并促进AIC发生和发展的复杂机制的重要性,为靶向治疗和个性化治疗方案提供了新途径。